{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IVA",
  "name": "Inventiva S.A.",
  "url": "https://frontierpicks.com/dossiers/IVA/",
  "json_url": "https://frontierpicks.com/dossiers/IVA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Single-asset MASH binary, still dormant: zero company news in the 30 days to 2026-08-23, with the undated Q4 2026 NATiV3 topline carrying the whole equity. RSI(14) firmed to 66.7 at the $4.68 close on no flow, while the $4.40 June offering price remains the structural reference. The 2026-09-25 H1 results are the next dated venue for runway and topline-timing language.",
  "invalidation_trigger": "A weekly close below $4.40 breaks the 2026-06-02 offering shelf and opens the prior-cycle low near $2.85; NATiV3 topline language moving off Q4 2026 at the 2026-09-25 H1 results would compound it by pushing the readout toward the end-Q2 2027 base-case runway.",
  "catalyst_date": "2026-09-25",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Foreign private issuer: reports on 6-K/20-F with half-year cadence, no 10-Q, and officers file no Form 4s. US insider screens are blank by structure, not by absence of activity.",
    "Dual-listed: ordinary shares on Euronext Paris, ADSs on Nasdaq. EUR/USD and the Paris session move the ADS independently of US-session news.",
    "Single-asset issuer: lanifibranor is effectively the entire pipeline value. A NATiV3 miss has no second program to cushion it.",
    "The 2026-07-29 release states current cash is not sufficient for the next 12 months of planned operations;",
    "NATiV3 topline is guided to Q4 2026 with no announced date. The readout is an unscheduled event window, not a calendar item.",
    "The company financial calendar labels the 2026-09-25 H1 results a Wednesday; 2026-09-25 is a Friday. The discrepancy has not been corrected."
  ],
  "body_markdown": "## Current Thesis\nNothing fundamental has moved since the 2026-07-30 correction release, and that absence is itself the current state of the name: no company announcement, no filing and no headline in the thirty days to 2026-08-23. The equity is still one thing — lanifibranor's NATiV3 Phase 3 topline, guided to Q4 2026 with no announced date — sitting on top of a funding structure the July disclosures made conditional. What did move is the tape: the close went from $4.60 on 2026-08-14 to $4.68 on 2026-08-21 while RSI(14) travelled from 50.0 to 66.7, a momentum reading that firmed on an empty news calendar. The shares remain -34.5% below the $7.15 52-week high and -7.7% over three months.\n\nThe narrative life-cycle reading is **maturing**. The attention events are behind it — the 2026-06-02 recapitalisation, the 2026-07-17 Cantor Fitzgerald Overweight initiation, the 2026-07-29 H1 release — and no new bid has arrived since. The S&P Global-polled panel of 13 analysts carried a mean target of $14.88 on 2026-08-23 (stockanalysis.com), against $15.13 on the same 13-name panel earlier in August: sell-side marks are drifting sideways-to-lower while the panel count is unchanged. Well known, still functioning, thin fresh flow.\n\n## Bull Case\n- NATiV3 randomised 1,009 patients in the main cohort against an original target of 969, plus 410 in the exploratory cohort against a 350 target (enrollment completion announced 2025-04-01). A 72-week histology endpoint from an April 2025 last-patient-in supports the company's own Q4 2026 topline guidance without requiring an extension.\n- Phase 2b NATIVE hit both resolution and fibrosis endpoints (NEJM, 2021). Lanifibranor is the only late-stage oral pan-PPAR (α/δ/γ) in MASH and carries FDA Breakthrough Therapy and Fast Track designations.\n- Base-case liquidity to end-Q2 2027 covers a Q4 2026 print with roughly two quarters of margin.\n- Burn is flat-to-down as the trial runs out: net cash used in operations was €48.7M in H1 2026 versus €53.7M in H1 2025, with €166.1M cash plus €67.8M of short-term deposits at 2026-06-30 (2026-07-29 release).\n- The commercial category already exists and is reimbursed. Rezdiffra was approved March 2024; semaglutide took a MASH label in August 2025. A positive fibrosis result reads into an established market.\n\n## Bear Case\n- The 2026-07-29 release states current cash \"is not sufficient to cover operating needs as currently planned for the next 12 months.\" Base-case runway is end-Q2 2027; a disclosure error on the single number that determines whether the funding gap closes.\n- Revenue was €0 in H1 2026 against €4.5M in H1 2025. No partnership income, no second program: a fibrosis miss or an ambiguous dual-endpoint result has nothing to fall back on.\n- The comparator bar hardened during enrollment. MAESTRO-NASH showed resolution 26–30% versus 10% placebo and fibrosis improvement 24–26% versus 14%; ESSENCE showed ~63% steatohepatitis resolution versus 34% placebo at 72 weeks. Lanifibranor reads out into a field where GLP-1 crossover is the standing question, and the combination-therapy framing that supports the bull case also implies lanifibranor is not the anchor agent.\n- Supply is recent and identifiable: 27.3M ADSs cleared at $4.40 on 2026-06-02, and the Tranche A convertible plus warrant tranches sit above the tape as unresolved share-count risk.\n- Consensus dispersion is extreme and not a signal of agreement. The 13-analyst S&P Global panel averages $14.88 with a high of $26 and a low of $8.80; a separate 7-analyst poll shows a $10.00 median with a $3.00–$20.00 range (August 2026). A panel spanning $3 to $26 is pricing two different outcomes, not one.\n\n## Setup & Price Structure\nThe $4.40 June offering price is the structural reference the whole tape is organised around; the 2026-08-21 close of $4.68 is above it and has not seriously threatened it since the placement. Distance to the $7.15 52-week high is -34.5%, and the three-month price change is -7.7% — the shares have gone nowhere over a quarter that contained a recapitalisation, an H1 release and a fresh Overweight initiation.\n\nPositioning observables, stated as observables: RSI(14) at 66.7 on 2026-08-21 is momentum firming inside a range rather than a breakout, since the same date sits a third below the 52-week high. Sell-side is positioned far ahead of the tape, with a $14.88 mean against a $4.68 close. US insider screens are structurally blank — as a foreign private issuer, Inventiva's officers file no Form 4s, so an absence of insider selling data is a reporting artefact and carries no information either way. The next scheduled company venue is 2026-09-25, thirty-three days from 2026-08-23, which puts an earnings date just outside the near window rather than inside it.\n\nOne calendar caveat carried forward: the 2026-07-29 financial calendar labels the 2026-09-25 H1 results a Wednesday, and 2026-09-25 is a Friday. The day mismatch has not been corrected in any release since.\n\n## Catalyst Calendar (next 30 days)\n- **No dated company event falls inside 2026-08-23 to 2026-09-22.** The window is empty by the company's own published calendar.\n- **2026-09-25 (confirmed, 33 days out)** — Full H1 2026 results, after U.S. market close. Third-party earnings calendars carry the same date (stockanalysis.com, 2026-08-23).\n- **~2026-H2 (est., undated)**\n- **~2026-Q4 (est., undated)** — NATiV3 Phase 3 topline, 72-week histology endpoints in ~1,000 F2–F3 patients. Unscheduled event window, not a calendar item.\n\n## What Would Change Our Mind\nThe structure that breaks first is the June placement shelf. A **weekly close below $4.40** ends the post-recapitalisation range and opens the prior-cycle low near $2.85, with no company-specific news required to get there — pre-readout holders reducing exposure into an undated binary is sufficient. Failure to reclaim $4.40 within two weeks of losing it would mark the placement as distribution rather than support.\n\nThe fundamental break is separate and comes on a date. If the 2026-09-25 H1 results move NATiV3 topline language off Q4 2026, the readout drifts toward the end-Q2 2027 base-case runway and the financing question reopens before there is any data to finance against.\n\nA dated topline announcement — an actual day, rather than a quarter — would do the same for the event risk.\n\n## Correlation Notes\n- Dual-listed structure: ordinary shares on Euronext Paris, ADSs on Nasdaq. EUR/USD and the Paris session move the ADS independent of any US-session news, and the Euronext consensus screens in euros (€13.35 average across 10 analysts, range €8.00–€22.31, TradingView, August 2026) against the dollar panel.\n- MASH complex read-through: headlines on Rezdiffra uptake (approved March 2024) and on semaglutide's August 2025 MASH label move the category's perceived TAM and the perceived crowding of it. The combination-therapy framing that has appeared in third-party commentary during 2026 argues the category is additive rather than winner-take-all — an argument that cuts both ways for a single-asset issuer.\n- Beta to small-cap biotech (XBI) and to rate expectations applies while the name is dormant; it decouples on the topline print, when the single-asset binary dominates every sector factor.\n- No US-listed pure comparator resolves on the same date. Nothing else in the MASH complex reads out on NATiV3's schedule, so there is no proxy that front-runs this specific result.",
  "first_seen": "2026-07-23",
  "last_analyzed": "2026-08-23T13:19:06+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}